Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Total Liabilities data on file, last reported at $26.3 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $26.3 million, up 282.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.3 million (up 282.69% YoY), and the FY2025 annual result was $26.7 million, up 264.28% from the prior year.
• Total Liabilities fell to $26.3 million in Q1 2026 per VVOS's latest filing, from $26.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $26.7 million in Q4 2025 and troughed at $6.9 million in Q1 2025.
• A 5-year average of $12.8 million and a median of $10.1 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities plunged 38.74% in 2025, then soared 282.69% in 2026.
• A 5-year view of Total Liabilities shows it stood at $8.9 million in 2022, then rose by 15.7% to $10.3 million in 2023, then dropped by 28.97% to $7.3 million in 2024, then surged by 264.28% to $26.7 million in 2025, then dropped by 1.47% to $26.3 million in 2026.
• Business Quant data shows VVOS's Total Liabilities at $26.3 million in Q1 2026, $26.7 million in Q4 2025, and $23.1 million in Q3 2025.